ANTIMICROBIAL RESISTANCE SOLUTIONS
WITH DR. JOHN H. REX
Latest Newsletters
Latest Government Action





















R&D Insight
Can you help?
Antimicrobial resistance poses a catastrophic threat. If we don’t act now, any one of us could go into hospital in 20 years for minor surgery and die because of an ordinary infection that can’t be treated by antibiotics. And routine operations like hip replacements or organ transplants could be deadly because of the risk of infection.
Dame Sally Davies Tweet


















Modeling the value of an effective antibiotic — Megiddo et al.
What does an antibiotic cost to develop? What is it worth? How to afford it?
COVID-19 and the Long-Term Trajectory of AMR Efforts: Wellcome Trust Deep Dive
IDSA White Paper on developing narrow-spectrum antimicrobials + editorial by G. Drusano
FDA: Early endpoints and late endpoints suggest a path to global regulatory convergence (Bart et al.)
Non-traditional antibiotics: A pipeline review and an analysis of key development challenges
Assessing antibiotic value: DTR, fire extinguishers, and a view from Australia
FDA Workshop: Animal models in support of narrow-spectrum agents for A. baumannii and P. aeruginosa
Plazomicin EU marketing application is withdrawn: Near zero market value of newly approved antibacterials
Push! Pull! Push! Pull! / Highlights from Davos 2018
Language matters: CRE vs. CPE; SDD vs. I; and MDR, XDR, PDR, UDR vs. DTR
Developing systemic & inhaled antibiotics for lung infections
The thoughtless person playing with penicillin treatment is morally responsible for the death of the man who succumbs to infection with the penicillin-resistant organism.
Alexander Fleming Tweet

The bipartisan PASTEUR Act is the strongest bill ever written to strengthen antibiotic development and use. It will fix our market failures, expand the pipeline for next generation antibiotics, and save lives. We can’t sit on our hands as this public health crisis arrives – we have to act now.
U.S. Senator Michael Bennet Tweet